NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $1.20 billion. The enterprise value is $1.00 billion.
Important Dates
The next confirmed earnings date is Thursday, April 30, 2026, before market open.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 113.79 million shares outstanding. The number of shares has increased by 3.37% in one year.
| Current Share Class | 113.79M |
| Shares Outstanding | 113.79M |
| Shares Change (YoY) | +3.37% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 9.34% |
| Owned by Institutions (%) | 76.86% |
| Float | 94.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.83 |
| Forward PS | 1.69 |
| PB Ratio | 3.49 |
| P/TBV Ratio | 3.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.90, with a Debt / Equity ratio of 0.73.
| Current Ratio | 2.90 |
| Quick Ratio | 2.51 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.70 |
Financial Efficiency
Return on equity (ROE) is -38.89% and return on invested capital (ROIC) is -120.11%.
| Return on Equity (ROE) | -38.89% |
| Return on Assets (ROA) | -9.06% |
| Return on Invested Capital (ROIC) | -120.11% |
| Return on Capital Employed (ROCE) | -25.52% |
| Weighted Average Cost of Capital (WACC) | 8.18% |
| Revenue Per Employee | $408,320 |
| Profits Per Employee | -$84,877 |
| Employee Count | 1,605 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 4.34 |
Taxes
| Income Tax | -23,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.78% in the last 52 weeks. The beta is 0.82, so NovoCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -39.78% |
| 50-Day Moving Average | 12.06 |
| 200-Day Moving Average | 13.07 |
| Relative Strength Index (RSI) | 37.75 |
| Average Volume (20 Days) | 1,185,033 |
Short Selling Information
The latest short interest is 8.52 million, so 7.49% of the outstanding shares have been sold short.
| Short Interest | 8.52M |
| Short Previous Month | 9.13M |
| Short % of Shares Out | 7.49% |
| Short % of Float | 9.00% |
| Short Ratio (days to cover) | 3.86 |
Income Statement
In the last 12 months, NovoCure had revenue of $655.35 million and -$136.23 million in losses. Loss per share was -$1.22.
| Revenue | 655.35M |
| Gross Profit | 490.18M |
| Operating Income | -148.29M |
| Pretax Income | -136.25M |
| Net Income | -136.23M |
| EBITDA | -135.16M |
| EBIT | -148.29M |
| Loss Per Share | -$1.22 |
Full Income StatementBalance Sheet
The company has $447.67 million in cash and $248.35 million in debt, with a net cash position of $199.32 million or $1.75 per share.
| Cash & Cash Equivalents | 447.67M |
| Total Debt | 248.35M |
| Net Cash | 199.32M |
| Net Cash Per Share | $1.75 |
| Equity (Book Value) | 340.47M |
| Book Value Per Share | 3.03 |
| Working Capital | 423.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$49.03 million and capital expenditures -$26.65 million, giving a free cash flow of -$75.68 million.
| Operating Cash Flow | -49.03M |
| Capital Expenditures | -26.65M |
| Depreciation & Amortization | 13.13M |
| Net Borrowing | -460.97M |
| Free Cash Flow | -75.68M |
| FCF Per Share | -$0.67 |
Full Cash Flow StatementMargins
Gross margin is 74.80%, with operating and profit margins of -22.63% and -20.79%.
| Gross Margin | 74.80% |
| Operating Margin | -22.63% |
| Pretax Margin | -20.79% |
| Profit Margin | -20.79% |
| EBITDA Margin | -20.62% |
| EBIT Margin | -22.63% |
| FCF Margin | n/a |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.37% |
| Shareholder Yield | -3.37% |
| Earnings Yield | -11.35% |
| FCF Yield | -6.30% |
Analyst Forecast
The average price target for NovoCure is $28.08, which is 166.16% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.08 |
| Price Target Difference | 166.16% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 23.41% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.95 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.95 |
| Piotroski F-Score | 3 |
